Literature DB >> 8055682

Pharmacokinetics of anti-infective agents in paediatric patients.

D R Butler1, R J Kuhn, M H Chandler.   

Abstract

Various differences in drug disposition exist between children and adults. For example, the volume of distribution (Vd) for many drugs is larger in children than in adults. Other parameters, including excretion and elimination may be altered in children compared with adults. The penicillins and cephalosporins are used commonly for the treatment of infection in paediatric patients. The increased Vd in children contributes to the increased elimination half-life of these agents. Clearance of the acylureido-penicillins is increased in children with cystic fibrosis, a disease that decreases the elimination half-life for these drugs. Aminoglycosides distribute into extracellular fluid and their pharmacokinetic profile is affected by changes in Vd. The Vd for aminoglycosides is slightly higher in children than in adults. Children with cystic fibrosis, burns, or cancer have higher clearance rates and larger Vd values for aminoglycosides. Few data in the literature address the pharmacokinetics of other anti-infective agents, including vancomycin, teicoplanin, erythromycin, metronidazole, chloramphenicol, and cotrimoxazole (trimethoprim-sulfamethoxazole), in children. Similarly, there is little information regarding the pharmacokinetic profile of antivirals and antifungals in children. Dosage guidelines are available to enable the clinician to initiate anti-infective therapy in children. Subsequent dosage requirements may change based on the patient's current clinical condition. Although several studies have investigated the pharmacokinetics of anti-infectives in neonates and adults, data for children are limited. Therefore, further studies are required so that the ever growing arsenal of anti-infectives can be administered appropriately to children.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8055682     DOI: 10.2165/00003088-199426050-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  111 in total

1.  Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses.

Authors:  D Tremblay; A Dupront; C Ho; D Coussediere; B Lenfant
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

2.  Dose-dependent pharmacokinetics of azlocillin compared to mezlocillin.

Authors:  T Bergan; S B Thorsteinsson; O Steingrimsson
Journal:  Chemotherapy       Date:  1982       Impact factor: 2.544

Review 3.  Pharmacokinetics and drug distribution during postnatal development.

Authors:  B M Assael
Journal:  Pharmacol Ther       Date:  1982       Impact factor: 12.310

Review 4.  Effect of maturation on drug disposition in pediatric patients.

Authors:  C F Stewart; E M Hampton
Journal:  Clin Pharm       Date:  1987-07

5.  Human pharmacokinetics of the antiviral drug DHPG.

Authors:  C Fletcher; R Sawchuk; B Chinnock; P de Miranda; H H Balfour
Journal:  Clin Pharmacol Ther       Date:  1986-09       Impact factor: 6.875

Review 6.  Overview of acyclovir pharmacokinetic disposition in adults and children.

Authors:  M R Blum; S H Liao; P de Miranda
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

7.  Pharmacokinetic comparison of intravenous and oral chloramphenicol in patients with Haemophilus influenzae meningitis.

Authors:  R Yogev; W M Kolling; T Williams
Journal:  Pediatrics       Date:  1981-05       Impact factor: 7.124

8.  Cerebrospinal fluid penetration of imipenem and cilastatin (primaxin) in children with central nervous system infections.

Authors:  R F Jacobs; G L Kearns; A L Brown; D C Longee
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

9.  Individualized aminoglycoside dosage regimens in patients with cystic fibrosis.

Authors:  G Delage; L Desautels; S Legault; R Lasalle; J G Lapierre; A Lamarre; P Masson; S Spier
Journal:  Drug Intell Clin Pharm       Date:  1988-05

10.  SERUM CONCENTRATION OF NAFCILLIN IN NEWBORN INFANTS AND CHILDREN.

Authors:  W J O'CONNOR; G H WARREN; P S MANDALA; L S EDRADA; S B ROSENMAN
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1964
View more
  13 in total

Review 1.  Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients.

Authors:  N Principi; S Esposito
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

2.  The Food and Drug Administration's deliberations on antidepressant use in pediatric patients.

Authors:  Laurel K Leslie; Thomas B Newman; P Joan Chesney; James M Perrin
Journal:  Pediatrics       Date:  2005-07       Impact factor: 7.124

3.  A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B.

Authors:  E M Sokal; E A Roberts; G Mieli-Vergani; P McPhillips; M Johnson; J Barber; N Dallow; E Boxall; D Kelly
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Gentamicin dosing for pediatric patients with congenital heart disease.

Authors:  Brady S Moffett; Sara J D Bork; Antonio R Mott
Journal:  Pediatr Cardiol       Date:  2010-06-12       Impact factor: 1.655

Review 5.  Antibiotics in neonatal infections: a review.

Authors:  V Fanos; A Dall'Agnola
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

6.  Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.

Authors:  D M Burger; A M van Rossum; P W Hugen; M H Suur; N G Hartwig; S P Geelen; H J Scherpbier; R M Hoetelmans; A G Vulto; R de Groot
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 7.  Macrolide antibiotics in paediatric infectious diseases.

Authors:  D R Guay
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

8.  Pharmacokinetics of teicoplanin in an ICU population of children and infants.

Authors:  John C Lukas; Georgios Karikas; Maria Gazouli; Panagiotis Kalabalikis; Tasos Hatzis; Panos Macheras
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

9.  Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.

Authors:  Stéphane Corvaisier; Bruno Charpiat; Cyril Mounier; Martine Wallon; Gilles Leboucher; Mounzer Al Kurdi; Jean-François Chaulet; François Peyron
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Influence of maturation and growth on cefetamet pivoxil pharmacokinetics: rational dosing for infants.

Authors:  W L Hayton; J Kneer; R de Groot; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.